Ryvu Therapeutics S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2024: -39.63%

Ryvu Therapeutics S.A. Return on Capital Employed (ROCE) is -39.63% for the year ending December 31, 2024, a 43.62% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Ryvu Therapeutics S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2023 was -27.59%, a 51.96% change year over year.
  • Ryvu Therapeutics S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -18.16%, a -55.46% change year over year.
  • Ryvu Therapeutics S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -40.77%, a 253.10% change year over year.
  • Ryvu Therapeutics S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -11.55%, a -59.77% change year over year.
Key Data
Date Return on Capital Employed (ROCE) Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share